<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00519376</url>
  </required_header>
  <id_info>
    <org_study_id>B2C110165</org_study_id>
    <nct_id>NCT00519376</nct_id>
  </id_info>
  <brief_title>A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In COPD Patients.</brief_title>
  <official_title>A Randomised, Single-dose, Dose Ascending, Double-blind, Placebo Controlled, Four-way, Incomplete Block Crossover Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Inhaled Doses of GW642444M With Magnesium Stearate in COPD Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will involve the use of a new compound, GW642444 that is being developed for the
      treatment of asthma and chronic obstructive pulmonary disease (COPD). It works by acting on
      cells in the lungs, causing some of the muscles around the lungs to relax and open up better
      (bronchodilation), making breathing easier. When a medicine is made into a form ready to be
      given to patients, the active ingredient is often prepared in the form of a salt, and
      inactive ingredients (excipients) are often added. Inactive ingredients might be used to help
      a medicine work better, to make it easier to produce the medicine, or to make it easier to
      get an accurate dose of medicine. In previous studies the study drug has been given as a dry
      powder in the form of either the 'H' salt (with the excipient lactose), or in the form of the
      'M' salt (with the excipients lactose and cellobiose octaacetate). In this study the 'M' salt
      form of the study drug has been prepared with lactose and a new excipient called magnesium
      stearate (instead of cellobiose octaacetate). Participants in this study will receive both
      the 'H' salt (GW642444H) and the new 'M' salt (GW642444M) containing magnesium stearate. This
      study will be the first time the new 'M' salt form of the study drug will be given to COPD
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period</measure>
    <time_frame>From the first dose of the study medication until the Follow-up Visit (up to Study Day 60)</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations. Refer to the General Adverse AE/SAE module for a complete list of AEs and SAEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, and White Blood Cell Count at 24 Hours Post-dose on Day 1 of Each Treatment Period</measure>
    <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
    <description>Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelet count, and white blood cell (WBC) count at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) at 24 Hours Post-dose on Day 1 of Each Treatment Period</measure>
    <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
    <description>Blood samples were collected for the measurement of hemoglobin and MCHC at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Reticulocyte and Red Blood Cell (RBC) Count at 24 Hours Post-dose on Day 1 of Each Treatment Period</measure>
    <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
    <description>Blood samples were collected for the measurement of reticulocyte and RBCs at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Hematocrit at 24 Hours Post-dose on Day 1 of Each Treatment Period</measure>
    <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
    <description>Blood samples were collected for the measurement of hematocrit at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Mean Corpuscle Volume (MCV) at 24 Hours Post-dose on Day 1 of Each Treatment Period</measure>
    <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
    <description>Blood samples were collected for the measurement of MCV at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Mean Corpuscle Hemoglobin (MCH) Values at 24 Hours Post-dose on Day 1 of Each Treatment Period</measure>
    <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
    <description>Blood samples were collected for the measurement of MCH at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase (CK) and Gamma Glutamyl Transferase (GGT) Values at 24 Hours Post-dose on Day 1 of Each Treatment Period</measure>
    <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
    <description>Blood samples were collected for the measurement of ALT, ALP, AST, and GGT at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Albumin and Total Protein at 24 Hours Post-dose on Day 1 of Each Treatment Period</measure>
    <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
    <description>Blood samples were collected for the measurement of albumin and total protein at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Cholesterol, Chloride, Potassium, Sodium, Triglycerides, and Urea at 24 Hours Post-dose on Day 1 of Each Treatment Period</measure>
    <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
    <description>Blood samples were collected for the measurement of cholesterol, chloride, potassium, sodium, triglycerides, and urea at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Total Bilirubin and Creatinine at 24 Hours Post-dose on Day 1 of Each Treatment Period</measure>
    <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
    <description>Blood samples were collected for the measurement of total bilirubin and creatinine at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in C-reactive Protein at 24 Hours Post-dose on Day 1 of Each Treatment Period</measure>
    <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
    <description>Blood samples were collected for the measurement of c-reactive protein at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Over the Post-dose 24 Hour (h) Period</measure>
    <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
    <description>SBP and DBP were measured at Baseline and over the post-dose 24 h period at the following scheduled time points: 20 minutes (M), 45 M, 1h, 2h, 3h, 4h, 6h, and 24 h. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Heart Rate Over the Post-dose 24 Hour (h) Period</measure>
    <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
    <description>Heart rate (HR) was measured at Baseline and over the post-dose 24 h period at the following scheduled time points: 20 minutes (M), 45 M, 1 h, 2 h, 3 h, 4 h, 6 h, and 24 h. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Electrocardiographic (ECG) Parameters Over the Post-dose 24 Hour (h) Period</measure>
    <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
    <description>ECG parameters [PR, QRS, RR, QT (uncorrected), QTcB (QT corrected by Bazett's formula) and QTcF (QT corrected by Fridericia's formula) intervals] were measured at Baseline and over the post-dose 24h period at the following scheduled time points: 20 minutes (min), 45 min, 1 h, 2 h, 3 h, 4 h, 6 h, and 24 h. Baseline was defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean FEV1 Over 23 and 24 Hours After Dosing</measure>
    <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
    <description>Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 was measured electronically by spirometry. The data is presented as adjusted mean of the FEV1 values over 23 and 24 hours after dosing. Changed in trough FEV1 will be analysed using a model with baseline, treatment, period, as fixed effects .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weighted Mean and Maximum Value (0 - 4 Hours) QTc(B) and QTc(F)</measure>
    <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
    <description>QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the 12-lead ECG. QTcB is the QT interval corrected for heart rate using Bazett's formula; QTcF is the QT interval corrected for heart rate using Fridericia's formula. Weighted mean (WM) is derived by calculating the area under curve (AUC), and then dividing by the relevant time interval. QTcB and QTcF recorded at 20 minutes, 45 minutes, 1, 2, 3, and 4 hours post-dose on Day 1 of each treatment period were used for analysis. The data is presented as the adjusted means of WM and maximum QTc(B) and QTc(F).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weighted Mean and Maximum Value (0 - 4 Hours) Supine Heart Rate</measure>
    <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
    <description>Weighted mean (WM) is derived by calculating the area under curve (AUC), and then dividing by the relevant time interval. Heart rate was recorded at Screening, prior to dosing, and at 20 minutes, 45 minutes, 1, 2, 3, 4 and 6 hours post-dose on Day 1of each treatment period. Heart rate recorded at 20 minutes, 45 minutes and 1, 2, 3 and 4 hours post-dose on Day 1of the each treatment period were used for analysis. Heart rate measurement was taken in a supine position having rested in this position for at least 10 minutes before each reading. The data is presented as adjusted mean of WM and maximum heart rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weighted Mean and Maximum Value (0 - 4 Hours) of Supine Systolic and Diastolic Blood Pressure</measure>
    <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
    <description>Blood pressure (BP) measurement included systolic blood pressure (SBP) and diastolic BP (DBP). Weighted mean (WM) is derived by calculating the area under curve (AUC), and then dividing by the relevant time interval. SBP and DBP were recorded at Screening, prior to dosing, and at 20 minutes, 45 minutes, 1,2, 3, 4 and 6 hours post-dose on Day 1of the each treatment period. SBP and DBP recorded at 20 minutes, 45 minutes and 1, 2, 3 and 4 hours post-dose on Day 1of the each treatment period were used for analysis. Heart rate measurement was taken in a supine position having rested in this position for at least 10 minutes before each reading. The data is presented as adjusted mean of WM and maximum SBP and DBP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weighted Mean and Maximum/Minimum Value (0 - 4 Hours) for Glucose and Potassium</measure>
    <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
    <description>Blood samples were collected for the measurement of potassium and glucose at Screening, prior to dosing, and at 20 minutes, 45 minutes, 1,2, 3 and 4 hours post-dose on Day 1of the each treatment period. Whole blood samples (approximately 1.0 milliliter [mL]) was analysed for potassium and glucose using the i-STAT1 portable chemical analyser. The i-STAT1 system is an analyser designed for point of care testing and employs a hand-held chemistry analyzer and disposable cartridges, which in the configuration tested, are capable of measuring potassium, glucose, blood gases, electrolytes, metabolites and coagulation. Weighted mean (WM) is derived by calculating the area under curve (AUC), and then dividing by the relevant time interval. The data is presented as adjusted mean of WM and maximum (max) glucose /minimum (min) potassium.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0- t) and up to 1 Hour Post-dose (AUC[0-1]) of GW642444 and Its Metabolites GI179710, GW630200, and GSK932009, After a Single Dose of GW642444</measure>
    <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
    <description>Blood samples were collected pre-dose and at 2, 5, 10, 20, and 30 minutes, 1, 2, 4, 6, 8, 10, and 24 hour post-dose. Blood samples were analyzed for GW642444 and its metabolites GI179710, GW630200 and GSK932009 using a high performance liquid chromatography/mass spectrometry/mass (HPLC/MS/MS) spectrometry. AUC defined as area under the plasma concentration curve from time zero to the last quantifiable concentration (AUC(0-t)), and up to 1 hour post-dose (AUC(0-1)) were determined by non-compartmental methods. Assay censoring refers to some of the values being below the limit of quantification such that this parameter could not be defined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of GW642444 and Its Metabolites GI179710, GW630200, and GSK932009, After a Single Dose of GW642444</measure>
    <time_frame>Day 1 of each treatment period (up to Study Day 54)</time_frame>
    <description>Blood samples were collected pre-dose and at 2, 5, 10, 20, and 30 minutes, 1, 2, 4, 6, 8, 10, and 24 hour post-dose. Blood samples were analyzed for GW642444 and its metabolites GI179710, GW630200 and GSK932009, using a high performance liquid chromatography/mass spectrometry/mass (HPLC/MS/MS) spectrometry. The maximum observed plasma concentration (Cmax) was determined from the concentration time data by non-compartmental methods. Assay censoring refers to some of the values being below the limit of quantification such that this parameter could not be defined.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax of GW642444 and Its Metabolites GI179710, GW630200, and GSK932009, After a Single Dose of GW642444</measure>
    <time_frame>Day 1 of each treatment period (up to Study Day 54)</time_frame>
    <description>Blood samples were collected pre-dose and at 2, 5, 10, 20, and 30 minutes, 1, 2, 4, 6, 8, 10, and 24 hour post-dose. Blood samples were analyzed for GW642444 and its metabolites GI179710, GW630200 and GSK932009, using a high performance liquid chromatography/mass spectrometry/mass (HPLC/MS/MS) spectrometry. The Time to maximum plasma concentration (Tmax) was determined from the concentration time data by non-compartmental methods. Assay censoring refers to some of the values being below the limit of quantification such that this parameter could not be defined.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>GW642444M 25mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GW642444M 50mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GW642444M 100mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GW642444H 100mcg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW642444M</intervention_name>
    <description>drug</description>
    <arm_group_label>GW642444M 50mcg</arm_group_label>
    <arm_group_label>GW642444M 100mcg</arm_group_label>
    <arm_group_label>GW642444M 25mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW642444H</intervention_name>
    <description>drug</description>
    <arm_group_label>GW642444H 100mcg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>GW642444H 100mcg</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_label>GW642444M 100mcg</arm_group_label>
    <arm_group_label>GW642444M 25mcg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male or female (of non-childbearing potential) &gt; or = 40 years

          -  History of COPD

          -  Smoker or ex-smoker

          -  Body weight &gt; or = 50 kg with BMI 18-32 kg/m2

        Exclusion criteria:

          -  History of significant disease

          -  Subjects with a primary asthma diagnosis

          -  Alpha-1 antitrypsin deficiency as underlying cause of COPD

          -  Recent respiratory tract infection

          -  Poorly controlled COPD

          -  Blood potassium level &lt; 3.5mmol/L

          -  Short-term or long tern oxygen therapy

          -  Recent participation in another trial

          -  History of drug or alcohol abuse

          -  Known allergies

          -  Recent blood donation

          -  ECG abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wiesbaden</city>
        <state>Hessen</state>
        <zip>65187</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mainz</city>
        <state>Rheinland-Pfalz</state>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>14057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013 Apr;26(2):256-64. doi: 10.1016/j.pupt.2012.12.001. Epub 2012 Dec 8.</citation>
    <PMID>23232038</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2007</study_first_submitted>
  <study_first_submitted_qc>August 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2007</study_first_posted>
  <results_first_submitted>June 12, 2013</results_first_submitted>
  <results_first_submitted_qc>December 5, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 30, 2013</results_first_posted>
  <disposition_first_submitted>July 22, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>July 22, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 10, 2009</disposition_first_posted>
  <last_update_submitted>February 3, 2017</last_update_submitted>
  <last_update_submitted_qc>February 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacodynamics,</keyword>
  <keyword>Chronic Obstructive Pulmonary Disease (COPD)</keyword>
  <keyword>safety,</keyword>
  <keyword>COPD patients</keyword>
  <keyword>pharmacokinetics,</keyword>
  <keyword>tolerability,</keyword>
  <keyword>GW642444,</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>B2C110165</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2C110165</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2C110165</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2C110165</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2C110165</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2C110165</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>B2C110165</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants meeting eligibility criteria at screening were randomized and entered a treatment period. Participants were then randomized to 4 treatment periods in one of 16 sequences (seq) each lasting 1 day and separated by a 7 - 14 day washout period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Seq 1: PB, GW642444M 25 µg, GW642444M 50 µg, GW642444M 100 µg</title>
          <description>Participants were administered single dose of the following treatments: Placebo (PB), GW642444M 25 µg, GW642444M 50 µg, GW642444M 100 µg. Each participants received doses in an ascending dose manner as per randomization from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
        </group>
        <group group_id="P2">
          <title>Seq 2: GW642444M 25 µg, PB, GW642444M 50 µg, GW642444M 100 µg</title>
          <description>Participants were administered single dose of the following treatments: GW642444M 25 µg, Placebo, GW642444M 50 µg, GW642444M 100 µg. Each participant received doses in an ascending dose manner as per randomization from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
        </group>
        <group group_id="P3">
          <title>Seq 3: GW642444M 25 µg, GW642444M 50 µg, PB, GW642444M 100 µg</title>
          <description>Participants were administered single dose of the following treatments: GW642444M 25 µg, GW642444M 50 µg, Placebo, GW642444M 100 µg. Each participant received doses in an ascending dose manner as per randomization from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
        </group>
        <group group_id="P4">
          <title>Seq 4: GW642444M 25 µg, GW642444M 50 µg, GW642444M 100 µg, PB</title>
          <description>Participants were administered single dose of the following treatments: GW642444M 25 µg, GW642444M 50 µg, GW642444M 100 µg, Placebo. Each participant received doses in an ascending dose manner as per randomization from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
        </group>
        <group group_id="P5">
          <title>Seq 5: PB, GW642444M 25 µg, GW642444M 50 µg, GW642444H 100 µg</title>
          <description>Participants were administered single dose of the following treatments: Placebo, GW642444M 25 µg, GW642444M 50 µg, GW642444H 100 µg. Each participant received doses in an ascending dose manner as per randomization from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
        </group>
        <group group_id="P6">
          <title>Seq 6: GW642444M 25 µg, PB, GW642444M 50 µg, GW642444H 100 µg</title>
          <description>Participants were administered single dose of the following treatments: GW642444M 25 µg, Placebo, GW642444M 50 µg, GW642444H 100 µg. Each participant received doses in an ascending dose manner as per randomization from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
        </group>
        <group group_id="P7">
          <title>Seq 7: GW642444M 25 µg, GW642444M 50 µg, PB, GW642444H 100 µg</title>
          <description>Participants were administered single dose of the following treatments: GW642444M 25 µg, GW642444M 50 µg, Placebo, GW642444H 100 µg. Each participant received doses in an ascending dose manner as per randomization from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
        </group>
        <group group_id="P8">
          <title>Seq 8: PB, GW642444M 25 µg, GW642444H 100 µg, GW642444M 50 µg</title>
          <description>Participants were administered single dose of the following treatments: Placebo, GW642444M 25 µg, GW642444H 100 µg, GW642444M 50 µg. Each participant received doses in an ascending dose manner as per randomization from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
        </group>
        <group group_id="P9">
          <title>Seq 9: GW642444M 25 µg, PB, GW642444H 100 µg, GW642444M 50 µg</title>
          <description>Participants were administered single dose of the following treatments: GW642444M 25 µg, Placebo, GW642444H 100 µg, GW642444M 50 µg. Each participant received doses in an ascending dose manner as per randomization from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
        </group>
        <group group_id="P10">
          <title>Seq 10: GW642444M 25 µg, GW642444M 50 µg, GW642444H 100 µg, PB</title>
          <description>Participants were administered single dose of the following treatments: GW642444M 25 µg, GW642444M 50 µg, GW642444H 100 µg, Placebo. Each participant received doses in an ascending dose manner as per randomization from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
        </group>
        <group group_id="P11">
          <title>Seq 11: PB, GW642444H 100 µg, GW642444M 25 µg, GW642444M 50 µg</title>
          <description>Participants were administered single dose of the following treatments: Placebo, GW642444H 100 µg, GW642444M 25 µg, GW642444M 50 µg. Each participant received doses in an ascending dose manner as per randomization from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
        </group>
        <group group_id="P12">
          <title>Seq 12: GW642444M 25 µg, GW642444H 100 µg, PB, GW642444M 50 µg</title>
          <description>Participants were administered single dose of the following treatments: GW642444M 25 µg, GW642444H 100 µg, Placebo, GW642444M 50 µg. Each participant received doses in an ascending dose manner as per randomization from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
        </group>
        <group group_id="P13">
          <title>Seq 13: GW642444M 25 µg, GW642444H 100 µg, GW642444M 50 µg, PB</title>
          <description>Participants were administered single dose of the following treatments: GW642444M 25 µg, GW642444H 100 µg, GW642444M 50 µg, Placebo. Each participant received doses in an ascending dose manner as per randomization from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
        </group>
        <group group_id="P14">
          <title>Seq 14: GW642444H 100 µg, PB, GW642444M 25 µg, GW642444M 50 µg</title>
          <description>Participants were administered single dose of the following treatments: GW642444H 100 µg, Placebo, GW642444M 25 µg, GW642444M 50 µg. Each participant received doses in an ascending dose manner as per randomization from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
        </group>
        <group group_id="P15">
          <title>Seq 15: GW642444H 100 µg, GW642444M 25 µg, PB, GW642444M 50 µg</title>
          <description>Participants were administered single dose of the following treatments: GW642444H 100 µg, GW642444M 25 µg, Placebo, GW642444M 50 µg. Each participant received doses in an ascending dose manner as per randomization from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
        </group>
        <group group_id="P16">
          <title>Seq 16: GW642444H 100 µg, GW642444M 25 µg, GW642444M 50 µg, PB</title>
          <description>Participants were administered single dose of the following treatments: GW642444H 100 µg, GW642444M 25µg, GW642444M 50 µg, Placebo. Each participant received doses in an ascending dose manner as per randomization from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unable Evaluate Cardiovascular Endpoints</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="1"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Treatment Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="1"/>
                <participants group_id="P15" count="1"/>
                <participants group_id="P16" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
                <participants group_id="P14" count="0"/>
                <participants group_id="P15" count="0"/>
                <participants group_id="P16" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GW642444M(25,50 and 100 µg),GW642444H(100 µg), PB in 1-16 Seq</title>
          <description>Participants were administered single dose of four of the five following treatments: GW642444M (25, 50 and 100 µg), GW642444H (100 µg) or placebo. Each participant received doses of GW642444M in an ascending dose manner with GW642444H and placebo randomly interspersed as per randomization from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.3" spread="7.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White/Caucasian/European Heritage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period</title>
        <description>An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations. Refer to the General Adverse AE/SAE module for a complete list of AEs and SAEs.</description>
        <time_frame>From the first dose of the study medication until the Follow-up Visit (up to Study Day 60)</time_frame>
        <population>All Subjects Population: all participants who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O2">
            <title>GW642444M 25 µg</title>
            <description>Participants received GW642444M 25 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O3">
            <title>GW642444M 50 µg</title>
            <description>Participants received GW642444M 50 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O4">
            <title>GW642444M 100 µg</title>
            <description>Participants received GW642444M 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O5">
            <title>GW642444H 100 µg</title>
            <description>Participants received GW642444H 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period</title>
          <description>An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A serious adverse event (SAE) is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect. Medical or scientific judgment should be exercised in deciding whether reporting is appropriate in other situations. Refer to the General Adverse AE/SAE module for a complete list of AEs and SAEs.</description>
          <population>All Subjects Population: all participants who received at least one dose of study medication</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, and White Blood Cell Count at 24 Hours Post-dose on Day 1 of Each Treatment Period</title>
        <description>Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelet count, and white blood cell (WBC) count at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
        <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
        <population>All Subjects Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the All Subjects Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O2">
            <title>GW642444M 25 µg</title>
            <description>Participants received GW642444M 25 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O3">
            <title>GW642444M 50 µg</title>
            <description>Participants received GW642444M 50 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O4">
            <title>GW642444M 100 µg</title>
            <description>Participants received GW642444M 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O5">
            <title>GW642444H 100 µg</title>
            <description>Participants received GW642444H 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Total Neutrophils, Platelet Count, and White Blood Cell Count at 24 Hours Post-dose on Day 1 of Each Treatment Period</title>
          <description>Blood samples were collected for the measurement of basophils, eosinophils, lymphocytes, monocytes, total neutrophils, platelet count, and white blood cell (WBC) count at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
          <population>All Subjects Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the All Subjects Population.</population>
          <units>10^9 cells per liter (GI/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils, n=19, 20, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.004" spread="0.0154"/>
                    <measurement group_id="O2" value="0.001" spread="0.0168"/>
                    <measurement group_id="O3" value="0.001" spread="0.0133"/>
                    <measurement group_id="O4" value="0.004" spread="0.0185"/>
                    <measurement group_id="O5" value="-0.004" spread="0.0211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils, n=19, 20, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.003" spread="0.1771"/>
                    <measurement group_id="O2" value="-0.045" spread="0.0707"/>
                    <measurement group_id="O3" value="-0.023" spread="0.0921"/>
                    <measurement group_id="O4" value="-0.031" spread="0.0895"/>
                    <measurement group_id="O5" value="-0.002" spread="0.0637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes, n=19, 20, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.068" spread="0.4094"/>
                    <measurement group_id="O2" value="0.021" spread="0.3719"/>
                    <measurement group_id="O3" value="-0.126" spread="0.2608"/>
                    <measurement group_id="O4" value="-0.146" spread="0.4055"/>
                    <measurement group_id="O5" value="-0.116" spread="0.3261"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes, n=19, 20, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.006" spread="0.1323"/>
                    <measurement group_id="O2" value="-0.027" spread="0.1390"/>
                    <measurement group_id="O3" value="0.007" spread="0.0917"/>
                    <measurement group_id="O4" value="-0.018" spread="0.1331"/>
                    <measurement group_id="O5" value="0.025" spread="0.1347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils, n=19, 20, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.100" spread="0.6174"/>
                    <measurement group_id="O2" value="0.188" spread="0.9814"/>
                    <measurement group_id="O3" value="0.343" spread="0.9674"/>
                    <measurement group_id="O4" value="0.201" spread="0.6165"/>
                    <measurement group_id="O5" value="-0.021" spread="0.7415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count, n=19, 20, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.0" spread="16.16"/>
                    <measurement group_id="O2" value="8.2" spread="18.38"/>
                    <measurement group_id="O3" value="8.5" spread="15.33"/>
                    <measurement group_id="O4" value="9.5" spread="13.72"/>
                    <measurement group_id="O5" value="-1.1" spread="10.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WBC, n=19, 20, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.807"/>
                    <measurement group_id="O2" value="0.14" spread="1.215"/>
                    <measurement group_id="O3" value="0.20" spread="1.029"/>
                    <measurement group_id="O4" value="0.04" spread="1.094"/>
                    <measurement group_id="O5" value="-0.12" spread="0.774"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) at 24 Hours Post-dose on Day 1 of Each Treatment Period</title>
        <description>Blood samples were collected for the measurement of hemoglobin and MCHC at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
        <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
        <population>All Subjects Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the All Subjects Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O2">
            <title>GW642444M 25 µg</title>
            <description>Participants received GW642444M 25 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O3">
            <title>GW642444M 50 µg</title>
            <description>Participants received GW642444M 50 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O4">
            <title>GW642444M 100 µg</title>
            <description>Participants received GW642444M 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O5">
            <title>GW642444H 100 µg</title>
            <description>Participants received GW642444H 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin and Mean Corpuscle Hemoglobin Concentration (MCHC) at 24 Hours Post-dose on Day 1 of Each Treatment Period</title>
          <description>Blood samples were collected for the measurement of hemoglobin and MCHC at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
          <population>All Subjects Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the All Subjects Population.</population>
          <units>Grams per liter (g/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin, n=19, 20, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="6.21"/>
                    <measurement group_id="O2" value="-1.2" spread="6.41"/>
                    <measurement group_id="O3" value="-0.5" spread="4.02"/>
                    <measurement group_id="O4" value="-3.0" spread="4.21"/>
                    <measurement group_id="O5" value="0.8" spread="5.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MCHC, n=19, 20, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="5.23"/>
                    <measurement group_id="O2" value="-5.8" spread="22.66"/>
                    <measurement group_id="O3" value="1.7" spread="5.58"/>
                    <measurement group_id="O4" value="5.3" spread="3.65"/>
                    <measurement group_id="O5" value="-0.8" spread="6.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Reticulocyte and Red Blood Cell (RBC) Count at 24 Hours Post-dose on Day 1 of Each Treatment Period</title>
        <description>Blood samples were collected for the measurement of reticulocyte and RBCs at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
        <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
        <population>All Subjects Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the All Subjects Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O2">
            <title>GW642444M 25 µg</title>
            <description>Participants received GW642444M 25 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O3">
            <title>GW642444M 50 µg</title>
            <description>Participants received GW642444M 50 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O4">
            <title>GW642444M 100 µg</title>
            <description>Participants received GW642444M 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O5">
            <title>GW642444H 100 µg</title>
            <description>Participants received GW642444H 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Reticulocyte and Red Blood Cell (RBC) Count at 24 Hours Post-dose on Day 1 of Each Treatment Period</title>
          <description>Blood samples were collected for the measurement of reticulocyte and RBCs at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
          <population>All Subjects Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the All Subjects Population.</population>
          <units>10^12 cells per liter (TI/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Reticulocytes, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00714" spread="0.021416"/>
                    <measurement group_id="O2" value="-0.00065" spread="0.019905"/>
                    <measurement group_id="O3" value="0.00208" spread="0.017391"/>
                    <measurement group_id="O4" value="0.00905" spread="0.016387"/>
                    <measurement group_id="O5" value="0.00094" spread="0.012676"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RBC, n=19, 20, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.194"/>
                    <measurement group_id="O2" value="0.01" spread="0.193"/>
                    <measurement group_id="O3" value="-0.01" spread="0.137"/>
                    <measurement group_id="O4" value="-0.11" spread="0.173"/>
                    <measurement group_id="O5" value="0.05" spread="0.186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Hematocrit at 24 Hours Post-dose on Day 1 of Each Treatment Period</title>
        <description>Blood samples were collected for the measurement of hematocrit at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
        <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
        <population>All Subjects Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the All Subjects Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O2">
            <title>GW642444M 25 µg</title>
            <description>Participants received GW642444M 25 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O3">
            <title>GW642444M 50 µg</title>
            <description>Participants received GW642444M 50 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O4">
            <title>GW642444M 100 µg</title>
            <description>Participants received GW642444M 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O5">
            <title>GW642444H 100 µg</title>
            <description>Participants received GW642444H 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hematocrit at 24 Hours Post-dose on Day 1 of Each Treatment Period</title>
          <description>Blood samples were collected for the measurement of hematocrit at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
          <population>All Subjects Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the All Subjects Population.</population>
          <units>Proportion of 1.0</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0044" spread="0.02025"/>
                    <measurement group_id="O2" value="-0.0024" spread="0.02132"/>
                    <measurement group_id="O3" value="-0.0018" spread="0.01674"/>
                    <measurement group_id="O4" value="-0.0161" spread="0.01408"/>
                    <measurement group_id="O5" value="0.0036" spread="0.02025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Corpuscle Volume (MCV) at 24 Hours Post-dose on Day 1 of Each Treatment Period</title>
        <description>Blood samples were collected for the measurement of MCV at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
        <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
        <population>Blood samples were collected for the measurement of MCV at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O2">
            <title>GW642444M 25 µg</title>
            <description>Participants received GW642444M 25 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O3">
            <title>GW642444M 50 µg</title>
            <description>Participants received GW642444M 50 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O4">
            <title>GW642444M 100 µg</title>
            <description>Participants received GW642444M 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O5">
            <title>GW642444H 100 µg</title>
            <description>Participants received GW642444H 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Corpuscle Volume (MCV) at 24 Hours Post-dose on Day 1 of Each Treatment Period</title>
          <description>Blood samples were collected for the measurement of MCV at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
          <population>Blood samples were collected for the measurement of MCV at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</population>
          <units>10^15 femtoliters (fL) per cell</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.67"/>
                    <measurement group_id="O2" value="-0.2" spread="2.09"/>
                    <measurement group_id="O3" value="-0.2" spread="1.96"/>
                    <measurement group_id="O4" value="-1.0" spread="0.76"/>
                    <measurement group_id="O5" value="-0.5" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Mean Corpuscle Hemoglobin (MCH) Values at 24 Hours Post-dose on Day 1 of Each Treatment Period</title>
        <description>Blood samples were collected for the measurement of MCH at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
        <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
        <population>All Subjects Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the All Subjects Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O2">
            <title>GW642444M 25 µg</title>
            <description>Participants received GW642444M 25 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O3">
            <title>GW642444M 50 µg</title>
            <description>Participants received GW642444M 50 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O4">
            <title>GW642444M 100 µg</title>
            <description>Participants received GW642444M 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O5">
            <title>GW642444H 100 µg</title>
            <description>Participants received GW642444H 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Mean Corpuscle Hemoglobin (MCH) Values at 24 Hours Post-dose on Day 1 of Each Treatment Period</title>
          <description>Blood samples were collected for the measurement of MCH at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
          <population>All Subjects Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the All Subjects Population.</population>
          <units>10^12 picograms (pg) per cell</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11" spread="0.403"/>
                    <measurement group_id="O2" value="-0.22" spread="0.465"/>
                    <measurement group_id="O3" value="0.24" spread="0.581"/>
                    <measurement group_id="O4" value="0.14" spread="0.342"/>
                    <measurement group_id="O5" value="-0.21" spread="0.528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase (CK) and Gamma Glutamyl Transferase (GGT) Values at 24 Hours Post-dose on Day 1 of Each Treatment Period</title>
        <description>Blood samples were collected for the measurement of ALT, ALP, AST, and GGT at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
        <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
        <population>All Subjects Population, Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the All Subjects Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O2">
            <title>GW642444M 25 µg</title>
            <description>Participants received GW642444M 25 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O3">
            <title>GW642444M 50 µg</title>
            <description>Participants received GW642444M 50 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O4">
            <title>GW642444M 100 µg</title>
            <description>Participants received GW642444M 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O5">
            <title>GW642444H 100 µg</title>
            <description>Participants received GW642444H 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Creatine Kinase (CK) and Gamma Glutamyl Transferase (GGT) Values at 24 Hours Post-dose on Day 1 of Each Treatment Period</title>
          <description>Blood samples were collected for the measurement of ALT, ALP, AST, and GGT at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
          <population>All Subjects Population, Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the All Subjects Population.</population>
          <units>International units per liter (IU/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT, n=17, 15, 17, 7, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="3.89"/>
                    <measurement group_id="O2" value="-0.5" spread="2.00"/>
                    <measurement group_id="O3" value="1.1" spread="2.75"/>
                    <measurement group_id="O4" value="-0.6" spread="1.51"/>
                    <measurement group_id="O5" value="1.0" spread="4.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP, n=17, 15, 17, 7, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="10.05"/>
                    <measurement group_id="O2" value="1.6" spread="4.90"/>
                    <measurement group_id="O3" value="0.6" spread="5.93"/>
                    <measurement group_id="O4" value="-0.4" spread="2.37"/>
                    <measurement group_id="O5" value="1.2" spread="6.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST, n=17, 13, 17, 6, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="5.46"/>
                    <measurement group_id="O2" value="-0.6" spread="2.87"/>
                    <measurement group_id="O3" value="-1.6" spread="2.69"/>
                    <measurement group_id="O4" value="-1.7" spread="1.03"/>
                    <measurement group_id="O5" value="2.1" spread="5.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GGT, n=17, 15, 17, 7, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="2.37"/>
                    <measurement group_id="O2" value="-0.9" spread="3.99"/>
                    <measurement group_id="O3" value="-0.5" spread="5.06"/>
                    <measurement group_id="O4" value="-1.6" spread="2.88"/>
                    <measurement group_id="O5" value="0.5" spread="5.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK n=17, 15, 17, 7, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.1" spread="29.90"/>
                    <measurement group_id="O2" value="-20.5" spread="36.07"/>
                    <measurement group_id="O3" value="-38.1" spread="69.67"/>
                    <measurement group_id="O4" value="-3.1" spread="15.99"/>
                    <measurement group_id="O5" value="-19.9" spread="20.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Albumin and Total Protein at 24 Hours Post-dose on Day 1 of Each Treatment Period</title>
        <description>Blood samples were collected for the measurement of albumin and total protein at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
        <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
        <population>All Subjects Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the All Subjects Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O2">
            <title>GW642444M 25 µg</title>
            <description>Participants received GW642444M 25 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O3">
            <title>GW642444M 50 µg</title>
            <description>Participants received GW642444M 50 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O4">
            <title>GW642444M 100 µg</title>
            <description>Participants received GW642444M 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O5">
            <title>GW642444H 100 µg</title>
            <description>Participants received GW642444H 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Albumin and Total Protein at 24 Hours Post-dose on Day 1 of Each Treatment Period</title>
          <description>Blood samples were collected for the measurement of albumin and total protein at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
          <population>All Subjects Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the All Subjects Population.</population>
          <units>Grams per liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin, n=17, 15, 17, 7, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="2.30"/>
                    <measurement group_id="O2" value="-0.1" spread="1.85"/>
                    <measurement group_id="O3" value="-0.2" spread="1.51"/>
                    <measurement group_id="O4" value="-0.9" spread="1.95"/>
                    <measurement group_id="O5" value="0.1" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein, n=17, 15, 17, 7, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="4.22"/>
                    <measurement group_id="O2" value="-0.5" spread="2.59"/>
                    <measurement group_id="O3" value="0.1" spread="2.34"/>
                    <measurement group_id="O4" value="-0.7" spread="3.40"/>
                    <measurement group_id="O5" value="0.8" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Cholesterol, Chloride, Potassium, Sodium, Triglycerides, and Urea at 24 Hours Post-dose on Day 1 of Each Treatment Period</title>
        <description>Blood samples were collected for the measurement of cholesterol, chloride, potassium, sodium, triglycerides, and urea at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
        <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
        <population>All Subjects Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the All Subjects Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O2">
            <title>GW642444M 25 µg</title>
            <description>Participants received GW642444M 25 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O3">
            <title>GW642444M 50 µg</title>
            <description>Participants received GW642444M 50 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O4">
            <title>GW642444M 100 µg</title>
            <description>Participants received GW642444M 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O5">
            <title>GW642444H 100 µg</title>
            <description>Participants received GW642444H 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cholesterol, Chloride, Potassium, Sodium, Triglycerides, and Urea at 24 Hours Post-dose on Day 1 of Each Treatment Period</title>
          <description>Blood samples were collected for the measurement of cholesterol, chloride, potassium, sodium, triglycerides, and urea at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
          <population>All Subjects Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the All Subjects Population.</population>
          <units>Millimoles per liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cholesterol, n=17, 15, 17, 7, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.085" spread="0.3416"/>
                    <measurement group_id="O2" value="0.121" spread="0.3764"/>
                    <measurement group_id="O3" value="0.032" spread="1.2588"/>
                    <measurement group_id="O4" value="-0.251" spread="0.5630"/>
                    <measurement group_id="O5" value="0.082" spread="0.2447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride, n=17, 15, 17, 7, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="2.65"/>
                    <measurement group_id="O2" value="0.0" spread="2.80"/>
                    <measurement group_id="O3" value="-0.3" spread="2.31"/>
                    <measurement group_id="O4" value="-0.3" spread="1.70"/>
                    <measurement group_id="O5" value="0.6" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium, n=17, 13, 17, 6, 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" spread="0.263"/>
                    <measurement group_id="O2" value="0.14" spread="0.384"/>
                    <measurement group_id="O3" value="0.06" spread="0.374"/>
                    <measurement group_id="O4" value="0.10" spread="0.358"/>
                    <measurement group_id="O5" value="0.16" spread="0.305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium, n=17, 15, 17, 7, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="2.03"/>
                    <measurement group_id="O2" value="-0.1" spread="1.83"/>
                    <measurement group_id="O3" value="0.4" spread="1.41"/>
                    <measurement group_id="O4" value="0.0" spread="1.15"/>
                    <measurement group_id="O5" value="0.9" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglyceride, n=17, 15, 17, 7, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.106" spread="0.4625"/>
                    <measurement group_id="O2" value="0.024" spread="0.5789"/>
                    <measurement group_id="O3" value="-0.015" spread="0.3800"/>
                    <measurement group_id="O4" value="-0.300" spread="0.5812"/>
                    <measurement group_id="O5" value="0.142" spread="0.2629"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea, n=17, 15, 17, 7, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="1.092"/>
                    <measurement group_id="O2" value="-0.17" spread="0.964"/>
                    <measurement group_id="O3" value="-0.38" spread="1.109"/>
                    <measurement group_id="O4" value="-0.17" spread="0.427"/>
                    <measurement group_id="O5" value="0.20" spread="0.918"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Total Bilirubin and Creatinine at 24 Hours Post-dose on Day 1 of Each Treatment Period</title>
        <description>Blood samples were collected for the measurement of total bilirubin and creatinine at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
        <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
        <population>All Subjects Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the All Subjects Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O2">
            <title>GW642444M 25 µg</title>
            <description>Participants received GW642444M 25 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O3">
            <title>GW642444M 50 µg</title>
            <description>Participants received GW642444M 50 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O4">
            <title>GW642444M 100 µg</title>
            <description>Participants received GW642444M 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O5">
            <title>GW642444H 100 µg</title>
            <description>Participants received GW642444H 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Bilirubin and Creatinine at 24 Hours Post-dose on Day 1 of Each Treatment Period</title>
          <description>Blood samples were collected for the measurement of total bilirubin and creatinine at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
          <population>All Subjects Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the All Subjects Population.</population>
          <units>Micromoles per liter (µmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="17"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Creatinine, n=17, 15, 17, 7, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="5.96"/>
                    <measurement group_id="O2" value="4.9" spread="5.62"/>
                    <measurement group_id="O3" value="4.9" spread="6.62"/>
                    <measurement group_id="O4" value="1.0" spread="5.07"/>
                    <measurement group_id="O5" value="1.5" spread="5.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin, n=17, 15, 17, 7, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="2.33"/>
                    <measurement group_id="O2" value="-0.1" spread="4.04"/>
                    <measurement group_id="O3" value="-0.8" spread="3.60"/>
                    <measurement group_id="O4" value="0.3" spread="1.38"/>
                    <measurement group_id="O5" value="1.0" spread="3.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in C-reactive Protein at 24 Hours Post-dose on Day 1 of Each Treatment Period</title>
        <description>Blood samples were collected for the measurement of c-reactive protein at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
        <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
        <population>All Subjects Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the All Subjects Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O2">
            <title>GW642444M 25 µg</title>
            <description>Participants received GW642444M 25 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O3">
            <title>GW642444M 50 µg</title>
            <description>Participants received GW642444M 50 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O4">
            <title>GW642444M 100 µg</title>
            <description>Participants received GW642444M 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O5">
            <title>GW642444H 100 µg</title>
            <description>Participants received GW642444H 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in C-reactive Protein at 24 Hours Post-dose on Day 1 of Each Treatment Period</title>
          <description>Blood samples were collected for the measurement of c-reactive protein at Baseline and 24 hours post-dose on Day 1of each treatment period. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
          <population>All Subjects Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the All Subjects Population.</population>
          <units>Milligrams per liter (Mg/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="3.837"/>
                    <measurement group_id="O2" value="0.20" spread="1.015"/>
                    <measurement group_id="O3" value="-0.47" spread="3.500"/>
                    <measurement group_id="O4" value="-0.76" spread="2.123"/>
                    <measurement group_id="O5" value="-0.93" spread="2.965"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Over the Post-dose 24 Hour (h) Period</title>
        <description>SBP and DBP were measured at Baseline and over the post-dose 24 h period at the following scheduled time points: 20 minutes (M), 45 M, 1h, 2h, 3h, 4h, 6h, and 24 h. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
        <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
        <population>All Subjects Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the All Subjects Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O2">
            <title>GW642444M 25 µg</title>
            <description>Participants received GW642444M 25 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O3">
            <title>GW642444M 50 µg</title>
            <description>Participants received GW642444M 50 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O4">
            <title>GW642444M 100 µg</title>
            <description>Participants received GW642444M 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O5">
            <title>GW642444H 100 µg</title>
            <description>Participants received GW642444H 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Over the Post-dose 24 Hour (h) Period</title>
          <description>SBP and DBP were measured at Baseline and over the post-dose 24 h period at the following scheduled time points: 20 minutes (M), 45 M, 1h, 2h, 3h, 4h, 6h, and 24 h. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
          <population>All Subjects Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the All Subjects Population.</population>
          <units>Millimeters of mercury (mmHg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP, 20 M, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="7.20"/>
                    <measurement group_id="O2" value="-0.6" spread="6.01"/>
                    <measurement group_id="O3" value="1.5" spread="4.59"/>
                    <measurement group_id="O4" value="0.2" spread="5.38"/>
                    <measurement group_id="O5" value="-5.2" spread="8.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 45 M, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="6.13"/>
                    <measurement group_id="O2" value="-0.5" spread="9.16"/>
                    <measurement group_id="O3" value="-2.6" spread="8.34"/>
                    <measurement group_id="O4" value="1.0" spread="7.12"/>
                    <measurement group_id="O5" value="-3.5" spread="8.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 1 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="8.11"/>
                    <measurement group_id="O2" value="-0.6" spread="5.83"/>
                    <measurement group_id="O3" value="-1.7" spread="8.46"/>
                    <measurement group_id="O4" value="-3.1" spread="10.20"/>
                    <measurement group_id="O5" value="-4.8" spread="5.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 2 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="7.77"/>
                    <measurement group_id="O2" value="-1.2" spread="9.23"/>
                    <measurement group_id="O3" value="0.6" spread="11.16"/>
                    <measurement group_id="O4" value="2.2" spread="7.73"/>
                    <measurement group_id="O5" value="-2.7" spread="6.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 3 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="7.58"/>
                    <measurement group_id="O2" value="0.9" spread="9.75"/>
                    <measurement group_id="O3" value="2.6" spread="7.92"/>
                    <measurement group_id="O4" value="4.7" spread="8.68"/>
                    <measurement group_id="O5" value="-0.1" spread="5.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 4 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="6.10"/>
                    <measurement group_id="O2" value="0.3" spread="9.99"/>
                    <measurement group_id="O3" value="0.7" spread="8.18"/>
                    <measurement group_id="O4" value="2.2" spread="7.59"/>
                    <measurement group_id="O5" value="-0.1" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 6 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="9.41"/>
                    <measurement group_id="O2" value="-1.4" spread="10.21"/>
                    <measurement group_id="O3" value="-0.7" spread="9.35"/>
                    <measurement group_id="O4" value="3.9" spread="9.82"/>
                    <measurement group_id="O5" value="-3.2" spread="9.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, 24 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="7.53"/>
                    <measurement group_id="O2" value="0.0" spread="9.01"/>
                    <measurement group_id="O3" value="-1.8" spread="8.70"/>
                    <measurement group_id="O4" value="3.5" spread="9.10"/>
                    <measurement group_id="O5" value="-5.3" spread="8.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 20 M, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="4.17"/>
                    <measurement group_id="O2" value="-0.9" spread="4.59"/>
                    <measurement group_id="O3" value="-0.6" spread="3.95"/>
                    <measurement group_id="O4" value="1.3" spread="1.93"/>
                    <measurement group_id="O5" value="-4.5" spread="7.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 45 M, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="4.65"/>
                    <measurement group_id="O2" value="-0.1" spread="6.53"/>
                    <measurement group_id="O3" value="-3.2" spread="5.91"/>
                    <measurement group_id="O4" value="0.9" spread="6.63"/>
                    <measurement group_id="O5" value="-3.8" spread="5.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 1 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.2" spread="7.12"/>
                    <measurement group_id="O2" value="-1.0" spread="4.46"/>
                    <measurement group_id="O3" value="-2.3" spread="4.81"/>
                    <measurement group_id="O4" value="-0.1" spread="9.03"/>
                    <measurement group_id="O5" value="-6.5" spread="5.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 2 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="6.65"/>
                    <measurement group_id="O2" value="0.2" spread="7.21"/>
                    <measurement group_id="O3" value="-1.7" spread="5.73"/>
                    <measurement group_id="O4" value="1.3" spread="6.35"/>
                    <measurement group_id="O5" value="-3.4" spread="8.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 3 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="7.32"/>
                    <measurement group_id="O2" value="-0.0" spread="5.94"/>
                    <measurement group_id="O3" value="-1.7" spread="5.62"/>
                    <measurement group_id="O4" value="2.5" spread="5.10"/>
                    <measurement group_id="O5" value="-4.0" spread="7.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 4 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="5.05"/>
                    <measurement group_id="O2" value="-0.6" spread="5.15"/>
                    <measurement group_id="O3" value="-1.7" spread="5.33"/>
                    <measurement group_id="O4" value="1.7" spread="5.08"/>
                    <measurement group_id="O5" value="-4.7" spread="7.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 6 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="7.03"/>
                    <measurement group_id="O2" value="-0.9" spread="6.05"/>
                    <measurement group_id="O3" value="-2.9" spread="5.05"/>
                    <measurement group_id="O4" value="-1.1" spread="5.61"/>
                    <measurement group_id="O5" value="-7.6" spread="7.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, 24 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="4.49"/>
                    <measurement group_id="O2" value="-0.5" spread="5.62"/>
                    <measurement group_id="O3" value="-1.4" spread="6.88"/>
                    <measurement group_id="O4" value="-0.1" spread="5.38"/>
                    <measurement group_id="O5" value="-4.1" spread="6.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Heart Rate Over the Post-dose 24 Hour (h) Period</title>
        <description>Heart rate (HR) was measured at Baseline and over the post-dose 24 h period at the following scheduled time points: 20 minutes (M), 45 M, 1 h, 2 h, 3 h, 4 h, 6 h, and 24 h. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
        <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
        <population>Per Protocol (PP) Population: all participants included in the All Subjects population excluding a participant deemed not to have heart rate or other ECG parameters deemed suitable for evaluation. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O2">
            <title>GW642444M 25 µg</title>
            <description>Participants received GW642444M 25 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O3">
            <title>GW642444M 50 µg</title>
            <description>Participants received GW642444M 50 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O4">
            <title>GW642444M 100 µg</title>
            <description>Participants received GW642444M 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O5">
            <title>GW642444H 100 µg</title>
            <description>Participants received GW642444H 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Heart Rate Over the Post-dose 24 Hour (h) Period</title>
          <description>Heart rate (HR) was measured at Baseline and over the post-dose 24 h period at the following scheduled time points: 20 minutes (M), 45 M, 1 h, 2 h, 3 h, 4 h, 6 h, and 24 h. Baseline is defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
          <population>Per Protocol (PP) Population: all participants included in the All Subjects population excluding a participant deemed not to have heart rate or other ECG parameters deemed suitable for evaluation. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).</population>
          <units>Beats per minute(bpm)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>20 M, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="4.49"/>
                    <measurement group_id="O2" value="0.7" spread="6.60"/>
                    <measurement group_id="O3" value="0.1" spread="5.58"/>
                    <measurement group_id="O4" value="2.2" spread="6.67"/>
                    <measurement group_id="O5" value="-2.4" spread="3.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 M, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="6.70"/>
                    <measurement group_id="O2" value="-0.2" spread="5.51"/>
                    <measurement group_id="O3" value="0.3" spread="5.49"/>
                    <measurement group_id="O4" value="4.0" spread="7.49"/>
                    <measurement group_id="O5" value="-1.9" spread="6.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="5.33"/>
                    <measurement group_id="O2" value="-2.1" spread="5.92"/>
                    <measurement group_id="O3" value="0.7" spread="6.74"/>
                    <measurement group_id="O4" value="1.7" spread="5.36"/>
                    <measurement group_id="O5" value="-2.2" spread="5.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="7.41"/>
                    <measurement group_id="O2" value="3.0" spread="11.76"/>
                    <measurement group_id="O3" value="3.3" spread="8.34"/>
                    <measurement group_id="O4" value="3.0" spread="7.00"/>
                    <measurement group_id="O5" value="-0.1" spread="7.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.7" spread="7.06"/>
                    <measurement group_id="O2" value="6.2" spread="13.76"/>
                    <measurement group_id="O3" value="0.7" spread="8.09"/>
                    <measurement group_id="O4" value="2.2" spread="6.84"/>
                    <measurement group_id="O5" value="0.4" spread="5.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="6.57"/>
                    <measurement group_id="O2" value="4.8" spread="13.87"/>
                    <measurement group_id="O3" value="2.0" spread="6.40"/>
                    <measurement group_id="O4" value="0.7" spread="7.72"/>
                    <measurement group_id="O5" value="0.1" spread="6.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="10.31"/>
                    <measurement group_id="O2" value="2.1" spread="14.37"/>
                    <measurement group_id="O3" value="6.0" spread="9.32"/>
                    <measurement group_id="O4" value="7.4" spread="11.35"/>
                    <measurement group_id="O5" value="3.6" spread="8.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="9.39"/>
                    <measurement group_id="O2" value="0.4" spread="9.05"/>
                    <measurement group_id="O3" value="0.2" spread="6.19"/>
                    <measurement group_id="O4" value="0.3" spread="11.35"/>
                    <measurement group_id="O5" value="-0.2" spread="7.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Electrocardiographic (ECG) Parameters Over the Post-dose 24 Hour (h) Period</title>
        <description>ECG parameters [PR, QRS, RR, QT (uncorrected), QTcB (QT corrected by Bazett's formula) and QTcF (QT corrected by Fridericia's formula) intervals] were measured at Baseline and over the post-dose 24h period at the following scheduled time points: 20 minutes (min), 45 min, 1 h, 2 h, 3 h, 4 h, 6 h, and 24 h. Baseline was defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
        <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
        <population>PP Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the PP Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O2">
            <title>GW642444M 25 µg</title>
            <description>Participants received GW642444M 25 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O3">
            <title>GW642444M 50 µg</title>
            <description>Participants received GW642444M 50 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O4">
            <title>GW642444M 100 µg</title>
            <description>Participants received GW642444M 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O5">
            <title>GW642444H 100 µg</title>
            <description>Participants received GW642444H 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Electrocardiographic (ECG) Parameters Over the Post-dose 24 Hour (h) Period</title>
          <description>ECG parameters [PR, QRS, RR, QT (uncorrected), QTcB (QT corrected by Bazett's formula) and QTcF (QT corrected by Fridericia's formula) intervals] were measured at Baseline and over the post-dose 24h period at the following scheduled time points: 20 minutes (min), 45 min, 1 h, 2 h, 3 h, 4 h, 6 h, and 24 h. Baseline was defined as the measurement at Screening (Day -28 to Day -1). Change from Baseline was calculated as the value at the post-Baseline time point minus the value at Baseline.</description>
          <population>PP Population. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles). Different participants may have been analyzed for different parameters, so the overall number of participants analyzed reflects everyone in the PP Population.</population>
          <units>milliseconds (msec)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PR, 20 min, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="17.172"/>
                    <measurement group_id="O2" value="-1.4" spread="15.486"/>
                    <measurement group_id="O3" value="1.0" spread="8.650"/>
                    <measurement group_id="O4" value="0.5" spread="11.295"/>
                    <measurement group_id="O5" value="-8.9" spread="15.095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, 45 min, n=19, 19, 19, 8, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.7" spread="7.846"/>
                    <measurement group_id="O2" value="-3.7" spread="15.106"/>
                    <measurement group_id="O3" value="1.3" spread="13.588"/>
                    <measurement group_id="O4" value="-4.5" spread="12.912"/>
                    <measurement group_id="O5" value="-4.7" spread="11.038"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, 1 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.8" spread="17.926"/>
                    <measurement group_id="O2" value="-2.7" spread="14.946"/>
                    <measurement group_id="O3" value="-1.7" spread="9.511"/>
                    <measurement group_id="O4" value="4.3" spread="19.070"/>
                    <measurement group_id="O5" value="-3.3" spread="12.014"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, 2 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.3" spread="12.978"/>
                    <measurement group_id="O2" value="-1.1" spread="11.047"/>
                    <measurement group_id="O3" value="-0.1" spread="13.800"/>
                    <measurement group_id="O4" value="-10.1" spread="44.279"/>
                    <measurement group_id="O5" value="2.8" spread="15.513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, 3 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="12.837"/>
                    <measurement group_id="O2" value="-3.1" spread="15.130"/>
                    <measurement group_id="O3" value="1.5" spread="10.602"/>
                    <measurement group_id="O4" value="2.8" spread="20.863"/>
                    <measurement group_id="O5" value="-3.3" spread="12.741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, 4 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="13.613"/>
                    <measurement group_id="O2" value="-1.7" spread="14.909"/>
                    <measurement group_id="O3" value="1.5" spread="11.102"/>
                    <measurement group_id="O4" value="16.98" spread="25.887"/>
                    <measurement group_id="O5" value="-2.5" spread="14.057"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, 6 h, n=18, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.0" spread="10.157"/>
                    <measurement group_id="O2" value="0.5" spread="15.174"/>
                    <measurement group_id="O3" value="-2.1" spread="9.437"/>
                    <measurement group_id="O4" value="23.59" spread="21.544"/>
                    <measurement group_id="O5" value="3.5" spread="11.536"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR, 24 h, n=19, 19, 18, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="18.636"/>
                    <measurement group_id="O2" value="-1.6" spread="17.618"/>
                    <measurement group_id="O3" value="0.4" spread="9.101"/>
                    <measurement group_id="O4" value="27.07" spread="20.769"/>
                    <measurement group_id="O5" value="2.1" spread="19.400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS, 20 min, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="5.031"/>
                    <measurement group_id="O2" value="-1.0" spread="3.886"/>
                    <measurement group_id="O3" value="0.6" spread="2.150"/>
                    <measurement group_id="O4" value="1.0" spread="4.719"/>
                    <measurement group_id="O5" value="1.4" spread="4.222"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS, 45 min, n=19, 19, 19, 8, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="4.789"/>
                    <measurement group_id="O2" value="0.2" spread="3.928"/>
                    <measurement group_id="O3" value="0.2" spread="3.534"/>
                    <measurement group_id="O4" value="0.0" spread="2.156"/>
                    <measurement group_id="O5" value="0.1" spread="4.601"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS, 1 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="5.562"/>
                    <measurement group_id="O2" value="-0.9" spread="4.449"/>
                    <measurement group_id="O3" value="-0.2" spread="2.155"/>
                    <measurement group_id="O4" value="2.7" spread="4.714"/>
                    <measurement group_id="O5" value="1.0" spread="4.958"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS, 2 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="5.393"/>
                    <measurement group_id="O2" value="-0.3" spread="3.888"/>
                    <measurement group_id="O3" value="0.7" spread="4.579"/>
                    <measurement group_id="O4" value="1.2" spread="1.265"/>
                    <measurement group_id="O5" value="-1.0" spread="6.513"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS, 3 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="6.324"/>
                    <measurement group_id="O2" value="1.2" spread="5.194"/>
                    <measurement group_id="O3" value="0.3" spread="3.045"/>
                    <measurement group_id="O4" value="0.9" spread="1.389"/>
                    <measurement group_id="O5" value="0.6" spread="4.670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS, 4 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="4.812"/>
                    <measurement group_id="O2" value="-0.9" spread="3.961"/>
                    <measurement group_id="O3" value="1.0" spread="4.937"/>
                    <measurement group_id="O4" value="1.0" spread="4.759"/>
                    <measurement group_id="O5" value="1.7" spread="3.666"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS, 6 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" spread="5.156"/>
                    <measurement group_id="O2" value="-0.1" spread="4.485"/>
                    <measurement group_id="O3" value="-0.0" spread="5.145"/>
                    <measurement group_id="O4" value="0.1" spread="4.254"/>
                    <measurement group_id="O5" value="2.0" spread="4.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QRS, 24 h, n=19, 19, 18, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.4" spread="6.090"/>
                    <measurement group_id="O2" value="-1.5" spread="3.736"/>
                    <measurement group_id="O3" value="0.7" spread="2.923"/>
                    <measurement group_id="O4" value="-0.0" spread="4.783"/>
                    <measurement group_id="O5" value="-0.5" spread="5.546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, 20 min, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9" spread="57.110"/>
                    <measurement group_id="O2" value="-9.0" spread="75.077"/>
                    <measurement group_id="O3" value="3.9" spread="73.786"/>
                    <measurement group_id="O4" value="-29.2" spread="123.015"/>
                    <measurement group_id="O5" value="4.7" spread="31.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, 45 min, n=19, 19, 19, 8, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="96.803"/>
                    <measurement group_id="O2" value="9.1" spread="65.366"/>
                    <measurement group_id="O3" value="-5.7" spread="81.079"/>
                    <measurement group_id="O4" value="-73.0" spread="130.999"/>
                    <measurement group_id="O5" value="4.0" spread="69.539"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, 1 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8" spread="91.489"/>
                    <measurement group_id="O2" value="39.9" spread="65.636"/>
                    <measurement group_id="O3" value="-3.7" spread="84.143"/>
                    <measurement group_id="O4" value="-29.1" spread="101.900"/>
                    <measurement group_id="O5" value="11.3" spread="66.621"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, 2 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="108.528"/>
                    <measurement group_id="O2" value="-25.1" spread="153.206"/>
                    <measurement group_id="O3" value="-24.2" spread="127.159"/>
                    <measurement group_id="O4" value="-29.3" spread="105.815"/>
                    <measurement group_id="O5" value="-15.3" spread="90.415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, 3 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.7" spread="95.030"/>
                    <measurement group_id="O2" value="-55.0" spread="175.742"/>
                    <measurement group_id="O3" value="5.6" spread="129.790"/>
                    <measurement group_id="O4" value="-35.7" spread="112.038"/>
                    <measurement group_id="O5" value="13.1" spread="78.368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, 4 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.9" spread="86.948"/>
                    <measurement group_id="O2" value="-54.7" spread="173.646"/>
                    <measurement group_id="O3" value="-24.6" spread="85.316"/>
                    <measurement group_id="O4" value="-17.9" spread="97.684"/>
                    <measurement group_id="O5" value="7.3" spread="94.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, 6 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-61.0" spread="125.922"/>
                    <measurement group_id="O2" value="-23.2" spread="183.705"/>
                    <measurement group_id="O3" value="-64.1" spread="127.976"/>
                    <measurement group_id="O4" value="-106.1" spread="160.044"/>
                    <measurement group_id="O5" value="-45.5" spread="71.133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RR, 24 h, n=19, 19, 18, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.7" spread="108.355"/>
                    <measurement group_id="O2" value="10.5" spread="95.865"/>
                    <measurement group_id="O3" value="6.0" spread="103.940"/>
                    <measurement group_id="O4" value="-1.6" spread="76.068"/>
                    <measurement group_id="O5" value="-18.8" spread="81.880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT, 20 min, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="15.094"/>
                    <measurement group_id="O2" value="-7.8" spread="13.891"/>
                    <measurement group_id="O3" value="-1.7" spread="9.306"/>
                    <measurement group_id="O4" value="2.2" spread="18.150"/>
                    <measurement group_id="O5" value="-2.7" spread="24.051"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT, 45 min, n=19, 19, 19, 8, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" spread="15.245"/>
                    <measurement group_id="O2" value="-0.8" spread="12.037"/>
                    <measurement group_id="O3" value="-0.1" spread="11.856"/>
                    <measurement group_id="O4" value="2.1" spread="8.750"/>
                    <measurement group_id="O5" value="0.3" spread="17.997"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT, 1 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.1" spread="14.820"/>
                    <measurement group_id="O2" value="1.3" spread="13.453"/>
                    <measurement group_id="O3" value="0.5" spread="13.096"/>
                    <measurement group_id="O4" value="2.6" spread="14.876"/>
                    <measurement group_id="O5" value="-0.1" spread="23.941"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT, 2 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="19.879"/>
                    <measurement group_id="O2" value="-9.2" spread="19.465"/>
                    <measurement group_id="O3" value="-5.6" spread="18.786"/>
                    <measurement group_id="O4" value="-10.5" spread="15.296"/>
                    <measurement group_id="O5" value="-0.7" spread="15.403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT, 3 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="21.154"/>
                    <measurement group_id="O2" value="-12.4" spread="28.408"/>
                    <measurement group_id="O3" value="0.8" spread="18.469"/>
                    <measurement group_id="O4" value="-10.8" spread="15.253"/>
                    <measurement group_id="O5" value="-1.6" spread="15.403"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT, 4 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" spread="27.773"/>
                    <measurement group_id="O2" value="-16.6" spread="29.661"/>
                    <measurement group_id="O3" value="-6.3" spread="14.699"/>
                    <measurement group_id="O4" value="-5.0" spread="16.399"/>
                    <measurement group_id="O5" value="-0.9" spread="16.693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT, 6 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.4" spread="22.329"/>
                    <measurement group_id="O2" value="-14.1" spread="26.540"/>
                    <measurement group_id="O3" value="-16.9" spread="20.348"/>
                    <measurement group_id="O4" value="-20.0" spread="22.842"/>
                    <measurement group_id="O5" value="-8.6" spread="11.990"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QT, 24 h, n=19, 19, 18, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.3" spread="39.366"/>
                    <measurement group_id="O2" value="-4.8" spread="19.461"/>
                    <measurement group_id="O3" value="1.1" spread="30.186"/>
                    <measurement group_id="O4" value="-0.3" spread="14.331"/>
                    <measurement group_id="O5" value="-1.1" spread="17.099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc(B), 20 min, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="10.206"/>
                    <measurement group_id="O2" value="-5.7" spread="18.465"/>
                    <measurement group_id="O3" value="-2.5" spread="13.058"/>
                    <measurement group_id="O4" value="7.6" spread="24.453"/>
                    <measurement group_id="O5" value="-4.8" spread="27.410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc(B), 45 min, n=19, 19, 19, 8, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="21.312"/>
                    <measurement group_id="O2" value="-2.8" spread="13.737"/>
                    <measurement group_id="O3" value="0.9" spread="13.972"/>
                    <measurement group_id="O4" value="18.5" spread="20.184"/>
                    <measurement group_id="O5" value="-1.8" spread="24.471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc(B), 1 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="19.298"/>
                    <measurement group_id="O2" value="-7.5" spread="15.779"/>
                    <measurement group_id="O3" value="1.2" spread="12.743"/>
                    <measurement group_id="O4" value="7.9" spread="11.202"/>
                    <measurement group_id="O5" value="-3.8" spread="30.201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc(B), 2 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="16.691"/>
                    <measurement group_id="O2" value="-3.9" spread="18.963"/>
                    <measurement group_id="O3" value="0.0" spread="16.015"/>
                    <measurement group_id="O4" value="-4.4" spread="22.214"/>
                    <measurement group_id="O5" value="2.1" spread="17.456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc(B), 3 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.8" spread="20.177"/>
                    <measurement group_id="O2" value="0.0" spread="19.550"/>
                    <measurement group_id="O3" value="0.4" spread="20.161"/>
                    <measurement group_id="O4" value="-3.8" spread="17.665"/>
                    <measurement group_id="O5" value="-3.9" spread="13.908"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc(B), 4 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="30.768"/>
                    <measurement group_id="O2" value="-4.4" spread="13.490"/>
                    <measurement group_id="O3" value="-1.3" spread="11.909"/>
                    <measurement group_id="O4" value="-1.5" spread="14.136"/>
                    <measurement group_id="O5" value="-1.6" spread="11.578"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc(B), 6 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="16.976"/>
                    <measurement group_id="O2" value="-9.3" spread="18.612"/>
                    <measurement group_id="O3" value="-2.9" spread="15.326"/>
                    <measurement group_id="O4" value="3.4" spread="12.821"/>
                    <measurement group_id="O5" value="2.0" spread="10.667"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc(B), 24 h, n=19, 19, 18, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" spread="32.387"/>
                    <measurement group_id="O2" value="-7.1" spread="15.386"/>
                    <measurement group_id="O3" value="-0.2" spread="14.676"/>
                    <measurement group_id="O4" value="0.3" spread="9.022"/>
                    <measurement group_id="O5" value="3.8" spread="18.294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc(F), 20 min, n=19, 19, 18, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="10.761"/>
                    <measurement group_id="O2" value="-6.5" spread="14.867"/>
                    <measurement group_id="O3" value="-2.2" spread="9.227"/>
                    <measurement group_id="O4" value="5.9" spread="19.428"/>
                    <measurement group_id="O5" value="-4.0" spread="26.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc(F), 45 min, n=19, 19, 19, 8, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" spread="16.508"/>
                    <measurement group_id="O2" value="-2.1" spread="11.430"/>
                    <measurement group_id="O3" value="0.6" spread="9.920"/>
                    <measurement group_id="O4" value="13.0" spread="12.102"/>
                    <measurement group_id="O5" value="-0.9" spread="20.795"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc(F), 1 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="15.088"/>
                    <measurement group_id="O2" value="-4.4" spread="13.387"/>
                    <measurement group_id="O3" value="1.0" spread="9.193"/>
                    <measurement group_id="O4" value="6.2" spread="8.626"/>
                    <measurement group_id="O5" value="-2.4" spread="26.900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc(F), 2 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="14.122"/>
                    <measurement group_id="O2" value="-5.8" spread="10.606"/>
                    <measurement group_id="O3" value="-2.0" spread="11.272"/>
                    <measurement group_id="O4" value="-6.5" spread="16.576"/>
                    <measurement group_id="O5" value="1.2" spread="13.750"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc(F), 3 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="17.341"/>
                    <measurement group_id="O2" value="-4.4" spread="13.383"/>
                    <measurement group_id="O3" value="0.5" spread="14.498"/>
                    <measurement group_id="O4" value="-6.2" spread="11.842"/>
                    <measurement group_id="O5" value="-3.2" spread="10.836"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc(F), 4 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="28.679"/>
                    <measurement group_id="O2" value="-8.8" spread="10.344"/>
                    <measurement group_id="O3" value="-3.0" spread="9.373"/>
                    <measurement group_id="O4" value="-2.7" spread="11.136"/>
                    <measurement group_id="O5" value="10.836" spread="8.648"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc(F), 6 h, n=19, 19, 19, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.7" spread="13.113"/>
                    <measurement group_id="O2" value="-11.1" spread="10.871"/>
                    <measurement group_id="O3" value="-7.8" spread="10.278"/>
                    <measurement group_id="O4" value="-4.7" spread="5.959"/>
                    <measurement group_id="O5" value="-1.7" spread="6.561"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>QTc(F), 24 h, n=19, 19, 18, 8, 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.2" spread="33.102"/>
                    <measurement group_id="O2" value="-6.4" spread="13.364"/>
                    <measurement group_id="O3" value="0.0" spread="17.882"/>
                    <measurement group_id="O4" value="0.0" spread="0.0"/>
                    <measurement group_id="O5" value="2.0" spread="15.496"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean FEV1 Over 23 and 24 Hours After Dosing</title>
        <description>Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 was measured electronically by spirometry. The data is presented as adjusted mean of the FEV1 values over 23 and 24 hours after dosing. Changed in trough FEV1 will be analysed using a model with baseline, treatment, period, as fixed effects .</description>
        <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
        <population>PP Population. Only those participants available at the indicated time points were assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O2">
            <title>GW642444M 25 µg</title>
            <description>Participants received GW642444M 25 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O3">
            <title>GW642444M 50 µg</title>
            <description>Participants received GW642444M 50 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O4">
            <title>GW642444M 100 µg</title>
            <description>Participants received GW642444M 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O5">
            <title>GW642444H 100 µg</title>
            <description>Participants received GW642444H 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean FEV1 Over 23 and 24 Hours After Dosing</title>
          <description>Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 was measured electronically by spirometry. The data is presented as adjusted mean of the FEV1 values over 23 and 24 hours after dosing. Changed in trough FEV1 will be analysed using a model with baseline, treatment, period, as fixed effects .</description>
          <population>PP Population. Only those participants available at the indicated time points were assessed.</population>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.432" spread="0.0402"/>
                    <measurement group_id="O2" value="1.622" spread="0.0431"/>
                    <measurement group_id="O3" value="1.638" spread="0.0415"/>
                    <measurement group_id="O4" value="1.642" spread="0.0650"/>
                    <measurement group_id="O5" value="1.569" spread="0.0501"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weighted Mean and Maximum Value (0 - 4 Hours) QTc(B) and QTc(F)</title>
        <description>QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the 12-lead ECG. QTcB is the QT interval corrected for heart rate using Bazett's formula; QTcF is the QT interval corrected for heart rate using Fridericia's formula. Weighted mean (WM) is derived by calculating the area under curve (AUC), and then dividing by the relevant time interval. QTcB and QTcF recorded at 20 minutes, 45 minutes, 1, 2, 3, and 4 hours post-dose on Day 1 of each treatment period were used for analysis. The data is presented as the adjusted means of WM and maximum QTc(B) and QTc(F).</description>
        <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
        <population>PP Population. Only those participants available at the indicated time points were assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O2">
            <title>GW642444M 25 µg</title>
            <description>Participants received GW642444M 25 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O3">
            <title>GW642444M 50 µg</title>
            <description>Participants received GW642444M 50 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O4">
            <title>GW642444M 100 µg</title>
            <description>Participants received GW642444M 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O5">
            <title>GW642444H 100 µg</title>
            <description>Participants received GW642444H 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>Weighted Mean and Maximum Value (0 - 4 Hours) QTc(B) and QTc(F)</title>
          <description>QT interval is a measure of the time between the start of the Q wave and the end of the T wave in the 12-lead ECG. QTcB is the QT interval corrected for heart rate using Bazett's formula; QTcF is the QT interval corrected for heart rate using Fridericia's formula. Weighted mean (WM) is derived by calculating the area under curve (AUC), and then dividing by the relevant time interval. QTcB and QTcF recorded at 20 minutes, 45 minutes, 1, 2, 3, and 4 hours post-dose on Day 1 of each treatment period were used for analysis. The data is presented as the adjusted means of WM and maximum QTc(B) and QTc(F).</description>
          <population>PP Population. Only those participants available at the indicated time points were assessed.</population>
          <units>Milliseconds (msec)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>WM QTcB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="419.68" spread="2.150"/>
                    <measurement group_id="O2" value="419.56" spread="2.378"/>
                    <measurement group_id="O3" value="424.18" spread="2.230"/>
                    <measurement group_id="O4" value="422.36" spread="3.517"/>
                    <measurement group_id="O5" value="419.70" spread="2.714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max QTcB</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="439.37" spread="3.714"/>
                    <measurement group_id="O2" value="437.06" spread="4.104"/>
                    <measurement group_id="O3" value="434.62" spread="3.850"/>
                    <measurement group_id="O4" value="438.14" spread="6.059"/>
                    <measurement group_id="O5" value="436.75" spread="4.681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WM QTcF,</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="409.13" spread="1.696"/>
                    <measurement group_id="O2" value="408.31" spread="1.898"/>
                    <measurement group_id="O3" value="412.99" spread="1.760"/>
                    <measurement group_id="O4" value="409.50" spread="2.842"/>
                    <measurement group_id="O5" value="409.82" spread="2.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max QTcF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="425.34" spread="2.900"/>
                    <measurement group_id="O2" value="421.73" spread="3.286"/>
                    <measurement group_id="O3" value="422.55" spread="3.025"/>
                    <measurement group_id="O4" value="422.41" spread="5.000"/>
                    <measurement group_id="O5" value="422.99" spread="3.766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weighted Mean and Maximum Value (0 - 4 Hours) Supine Heart Rate</title>
        <description>Weighted mean (WM) is derived by calculating the area under curve (AUC), and then dividing by the relevant time interval. Heart rate was recorded at Screening, prior to dosing, and at 20 minutes, 45 minutes, 1, 2, 3, 4 and 6 hours post-dose on Day 1of each treatment period. Heart rate recorded at 20 minutes, 45 minutes and 1, 2, 3 and 4 hours post-dose on Day 1of the each treatment period were used for analysis. Heart rate measurement was taken in a supine position having rested in this position for at least 10 minutes before each reading. The data is presented as adjusted mean of WM and maximum heart rate.</description>
        <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
        <population>PP Population. Only those participants available at the indicated time points were assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O2">
            <title>GW642444M 25 µg</title>
            <description>Participants received GW642444M 25 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O3">
            <title>GW642444M 50 µg</title>
            <description>Participants received GW642444M 50 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O4">
            <title>GW642444M 100 µg</title>
            <description>Participants received GW642444M 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O5">
            <title>GW642444H 100 µg</title>
            <description>Participants received GW642444H 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>Weighted Mean and Maximum Value (0 - 4 Hours) Supine Heart Rate</title>
          <description>Weighted mean (WM) is derived by calculating the area under curve (AUC), and then dividing by the relevant time interval. Heart rate was recorded at Screening, prior to dosing, and at 20 minutes, 45 minutes, 1, 2, 3, 4 and 6 hours post-dose on Day 1of each treatment period. Heart rate recorded at 20 minutes, 45 minutes and 1, 2, 3 and 4 hours post-dose on Day 1of the each treatment period were used for analysis. Heart rate measurement was taken in a supine position having rested in this position for at least 10 minutes before each reading. The data is presented as adjusted mean of WM and maximum heart rate.</description>
          <population>PP Population. Only those participants available at the indicated time points were assessed.</population>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>WM Heart rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.12" spread="1.320"/>
                    <measurement group_id="O2" value="71.76" spread="1.473"/>
                    <measurement group_id="O3" value="71.57" spread="1.377"/>
                    <measurement group_id="O4" value="73.50" spread="2.179"/>
                    <measurement group_id="O5" value="71.22" spread="1.734"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max Heart rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.88" spread="1.784"/>
                    <measurement group_id="O2" value="79.95" spread="1.948"/>
                    <measurement group_id="O3" value="76.13" spread="1.845"/>
                    <measurement group_id="O4" value="77.77" spread="2.764"/>
                    <measurement group_id="O5" value="77.16" spread="2.248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weighted Mean and Maximum Value (0 - 4 Hours) of Supine Systolic and Diastolic Blood Pressure</title>
        <description>Blood pressure (BP) measurement included systolic blood pressure (SBP) and diastolic BP (DBP). Weighted mean (WM) is derived by calculating the area under curve (AUC), and then dividing by the relevant time interval. SBP and DBP were recorded at Screening, prior to dosing, and at 20 minutes, 45 minutes, 1,2, 3, 4 and 6 hours post-dose on Day 1of the each treatment period. SBP and DBP recorded at 20 minutes, 45 minutes and 1, 2, 3 and 4 hours post-dose on Day 1of the each treatment period were used for analysis. Heart rate measurement was taken in a supine position having rested in this position for at least 10 minutes before each reading. The data is presented as adjusted mean of WM and maximum SBP and DBP.</description>
        <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
        <population>PP Population. Only those participants available at the indicated time points were assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O2">
            <title>GW642444M 25 µg</title>
            <description>Participants received GW642444M 25 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O3">
            <title>GW642444M 50 µg</title>
            <description>Participants received GW642444M 50 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O4">
            <title>GW642444M 100 µg</title>
            <description>Participants received GW642444M 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O5">
            <title>GW642444H 100 µg</title>
            <description>Participants received GW642444H 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>Weighted Mean and Maximum Value (0 - 4 Hours) of Supine Systolic and Diastolic Blood Pressure</title>
          <description>Blood pressure (BP) measurement included systolic blood pressure (SBP) and diastolic BP (DBP). Weighted mean (WM) is derived by calculating the area under curve (AUC), and then dividing by the relevant time interval. SBP and DBP were recorded at Screening, prior to dosing, and at 20 minutes, 45 minutes, 1,2, 3, 4 and 6 hours post-dose on Day 1of the each treatment period. SBP and DBP recorded at 20 minutes, 45 minutes and 1, 2, 3 and 4 hours post-dose on Day 1of the each treatment period were used for analysis. Heart rate measurement was taken in a supine position having rested in this position for at least 10 minutes before each reading. The data is presented as adjusted mean of WM and maximum SBP and DBP.</description>
          <population>PP Population. Only those participants available at the indicated time points were assessed.</population>
          <units>Millimeters of mercury</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>WM SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126.92" spread="1.223"/>
                    <measurement group_id="O2" value="126.28" spread="1.388"/>
                    <measurement group_id="O3" value="127.82" spread="1.284"/>
                    <measurement group_id="O4" value="128.99" spread="2.146"/>
                    <measurement group_id="O5" value="125.10" spread="1.621"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="133.23" spread="1.521"/>
                    <measurement group_id="O2" value="133.06" spread="1.714"/>
                    <measurement group_id="O3" value="133.91" spread="1.591"/>
                    <measurement group_id="O4" value="135.24" spread="2.625"/>
                    <measurement group_id="O5" value="131.13" spread="1.994"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WM DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.36" spread="1.017"/>
                    <measurement group_id="O2" value="79.74" spread="1.133"/>
                    <measurement group_id="O3" value="80.04" spread="1.056"/>
                    <measurement group_id="O4" value="83.46" spread="1.721"/>
                    <measurement group_id="O5" value="77.46" spread="1.321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.13" spread="1.147"/>
                    <measurement group_id="O2" value="75.08" spread="1.272"/>
                    <measurement group_id="O3" value="76.30" spread="1.189"/>
                    <measurement group_id="O4" value="79.92" spread="1.917"/>
                    <measurement group_id="O5" value="71.63" spread="1.478"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weighted Mean and Maximum/Minimum Value (0 - 4 Hours) for Glucose and Potassium</title>
        <description>Blood samples were collected for the measurement of potassium and glucose at Screening, prior to dosing, and at 20 minutes, 45 minutes, 1,2, 3 and 4 hours post-dose on Day 1of the each treatment period. Whole blood samples (approximately 1.0 milliliter [mL]) was analysed for potassium and glucose using the i-STAT1 portable chemical analyser. The i-STAT1 system is an analyser designed for point of care testing and employs a hand-held chemistry analyzer and disposable cartridges, which in the configuration tested, are capable of measuring potassium, glucose, blood gases, electrolytes, metabolites and coagulation. Weighted mean (WM) is derived by calculating the area under curve (AUC), and then dividing by the relevant time interval. The data is presented as adjusted mean of WM and maximum (max) glucose /minimum (min) potassium.</description>
        <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
        <population>PP Population. Only those participants available at the indicated time points were assessed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O2">
            <title>GW642444M 25 µg</title>
            <description>Participants received GW642444M 25 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O3">
            <title>GW642444M 50 µg</title>
            <description>Participants received GW642444M 50 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O4">
            <title>GW642444M 100 µg</title>
            <description>Participants received GW642444M 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O5">
            <title>GW642444H 100 µg</title>
            <description>Participants received GW642444H 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>Weighted Mean and Maximum/Minimum Value (0 - 4 Hours) for Glucose and Potassium</title>
          <description>Blood samples were collected for the measurement of potassium and glucose at Screening, prior to dosing, and at 20 minutes, 45 minutes, 1,2, 3 and 4 hours post-dose on Day 1of the each treatment period. Whole blood samples (approximately 1.0 milliliter [mL]) was analysed for potassium and glucose using the i-STAT1 portable chemical analyser. The i-STAT1 system is an analyser designed for point of care testing and employs a hand-held chemistry analyzer and disposable cartridges, which in the configuration tested, are capable of measuring potassium, glucose, blood gases, electrolytes, metabolites and coagulation. Weighted mean (WM) is derived by calculating the area under curve (AUC), and then dividing by the relevant time interval. The data is presented as adjusted mean of WM and maximum (max) glucose /minimum (min) potassium.</description>
          <population>PP Population. Only those participants available at the indicated time points were assessed.</population>
          <units>Millimoles per liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>WM Glucose, n=16,18,19,6,10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.94" spread="0.204"/>
                    <measurement group_id="O2" value="5.86" spread="0.227"/>
                    <measurement group_id="O3" value="5.95" spread="0.200"/>
                    <measurement group_id="O4" value="6.25" spread="0.345"/>
                    <measurement group_id="O5" value="5.71" spread="0.251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max Glucose, n=17, 20, 19, 6,10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.73" spread="0.342"/>
                    <measurement group_id="O2" value="6.61" spread="0.370"/>
                    <measurement group_id="O3" value="6.65" spread="0.342"/>
                    <measurement group_id="O4" value="6.99" spread="0.608"/>
                    <measurement group_id="O5" value="6.09" spread="0.436"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WM Potassium, n=15, 16, 17, 5,12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.29" spread="0.058"/>
                    <measurement group_id="O2" value="4.29" spread="0.067"/>
                    <measurement group_id="O3" value="4.14" spread="0.057"/>
                    <measurement group_id="O4" value="4.22" spread="0.102"/>
                    <measurement group_id="O5" value="4.27" spread="0.073"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Min Potassium, n=16, 20, 18, 6,12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.02" spread="0.052"/>
                    <measurement group_id="O2" value="4.03" spread="0.053"/>
                    <measurement group_id="O3" value="3.97" spread="0.052"/>
                    <measurement group_id="O4" value="4.08" spread="0.082"/>
                    <measurement group_id="O5" value="4.08" spread="0.065"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC(0- t) and up to 1 Hour Post-dose (AUC[0-1]) of GW642444 and Its Metabolites GI179710, GW630200, and GSK932009, After a Single Dose of GW642444</title>
        <description>Blood samples were collected pre-dose and at 2, 5, 10, 20, and 30 minutes, 1, 2, 4, 6, 8, 10, and 24 hour post-dose. Blood samples were analyzed for GW642444 and its metabolites GI179710, GW630200 and GSK932009 using a high performance liquid chromatography/mass spectrometry/mass (HPLC/MS/MS) spectrometry. AUC defined as area under the plasma concentration curve from time zero to the last quantifiable concentration (AUC(0-t)), and up to 1 hour post-dose (AUC(0-1)) were determined by non-compartmental methods. Assay censoring refers to some of the values being below the limit of quantification such that this parameter could not be defined.</description>
        <time_frame>Baseline and Day 1 of each treatment period (up to Study Day 54)</time_frame>
        <population>Pharmacokinetic (PK) Population: all participants who received at least one dose and for whom a PK sample was obtained and analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O2">
            <title>GW642444M 25 µg</title>
            <description>Participants received GW642444M 25 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O3">
            <title>GW642444M 50 µg</title>
            <description>Participants received GW642444M 50 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O4">
            <title>GW642444M 100 µg</title>
            <description>Participants received GW642444M 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O5">
            <title>GW642444H 100 µg</title>
            <description>Participants received GW642444H 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>AUC(0- t) and up to 1 Hour Post-dose (AUC[0-1]) of GW642444 and Its Metabolites GI179710, GW630200, and GSK932009, After a Single Dose of GW642444</title>
          <description>Blood samples were collected pre-dose and at 2, 5, 10, 20, and 30 minutes, 1, 2, 4, 6, 8, 10, and 24 hour post-dose. Blood samples were analyzed for GW642444 and its metabolites GI179710, GW630200 and GSK932009 using a high performance liquid chromatography/mass spectrometry/mass (HPLC/MS/MS) spectrometry. AUC defined as area under the plasma concentration curve from time zero to the last quantifiable concentration (AUC(0-t)), and up to 1 hour post-dose (AUC(0-1)) were determined by non-compartmental methods. Assay censoring refers to some of the values being below the limit of quantification such that this parameter could not be defined.</description>
          <population>Pharmacokinetic (PK) Population: all participants who received at least one dose and for whom a PK sample was obtained and analyzed</population>
          <units>picograms.Hour/milliliter (pg.hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GW642444, AUC(0-t), n=0, 17, 19, 8, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="56.49" spread="86.2"/>
                    <measurement group_id="O3" value="222.36" spread="96.5"/>
                    <measurement group_id="O4" value="572.99" spread="45.3"/>
                    <measurement group_id="O5" value="98.13" spread="0.782"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GW64244, AUC(0-1), n=0, 11, 18, 8, 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="58.01" spread="25.4"/>
                    <measurement group_id="O3" value="106.31" spread="44.5"/>
                    <measurement group_id="O4" value="196.24" spread="23.9"/>
                    <measurement group_id="O5" value="54.85" spread="28.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI179710, AUC (0-t), n=0, 0, 0, 1, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA">Insufficient data to define due to assay censoring.</measurement>
                    <measurement group_id="O3" value="NA">Insufficient data to define due to assay censoring.</measurement>
                    <measurement group_id="O4" value="NA">Insufficient data to define due to assay censoring.</measurement>
                    <measurement group_id="O5" value="NA">Insufficient data to define due to assay censoring.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GW630200, AUC(0-t), n=0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA">Insufficient data to define due to assay censoring.</measurement>
                    <measurement group_id="O3" value="NA">Insufficient data to define due to assay censoring.</measurement>
                    <measurement group_id="O4" value="NA">Insufficient data to define due to assay censoring.</measurement>
                    <measurement group_id="O5" value="NA">Insufficient data to define due to assay censoring.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK932009, AUC(0-t), n=0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA">Insufficient data to define due to assay censoring.</measurement>
                    <measurement group_id="O3" value="NA">Insufficient data to define due to assay censoring.</measurement>
                    <measurement group_id="O4" value="NA">Insufficient data to define due to assay censoring.</measurement>
                    <measurement group_id="O5" value="NA">Insufficient data to define due to assay censoring.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax of GW642444 and Its Metabolites GI179710, GW630200, and GSK932009, After a Single Dose of GW642444</title>
        <description>Blood samples were collected pre-dose and at 2, 5, 10, 20, and 30 minutes, 1, 2, 4, 6, 8, 10, and 24 hour post-dose. Blood samples were analyzed for GW642444 and its metabolites GI179710, GW630200 and GSK932009, using a high performance liquid chromatography/mass spectrometry/mass (HPLC/MS/MS) spectrometry. The maximum observed plasma concentration (Cmax) was determined from the concentration time data by non-compartmental methods. Assay censoring refers to some of the values being below the limit of quantification such that this parameter could not be defined.</description>
        <time_frame>Day 1 of each treatment period (up to Study Day 54)</time_frame>
        <population>PK Population: all participants who received at least one dose and for whom a PK sample was obtained and analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O2">
            <title>GW642444M 25 µg</title>
            <description>Participants received GW642444M 25 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O3">
            <title>GW642444M 50 µg</title>
            <description>Participants received GW642444M 50 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O4">
            <title>GW642444M 100 µg</title>
            <description>Participants received GW642444M 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O5">
            <title>GW642444H 100 µg</title>
            <description>Participants received GW642444H 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax of GW642444 and Its Metabolites GI179710, GW630200, and GSK932009, After a Single Dose of GW642444</title>
          <description>Blood samples were collected pre-dose and at 2, 5, 10, 20, and 30 minutes, 1, 2, 4, 6, 8, 10, and 24 hour post-dose. Blood samples were analyzed for GW642444 and its metabolites GI179710, GW630200 and GSK932009, using a high performance liquid chromatography/mass spectrometry/mass (HPLC/MS/MS) spectrometry. The maximum observed plasma concentration (Cmax) was determined from the concentration time data by non-compartmental methods. Assay censoring refers to some of the values being below the limit of quantification such that this parameter could not be defined.</description>
          <population>PK Population: all participants who received at least one dose and for whom a PK sample was obtained and analyzed</population>
          <units>picograms/milliliter (pg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GW642444,n=0, 20, 19, 8, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="78.16" spread="43.9"/>
                    <measurement group_id="O3" value="150.60" spread="53.1"/>
                    <measurement group_id="O4" value="259.96" spread="22.2"/>
                    <measurement group_id="O5" value="73.70" spread="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI179710,n=0, 0, 4, 7, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA">Insufficient data to define due to assay censoring.</measurement>
                    <measurement group_id="O3" value="NA">Insufficient data to define due to assay censoring.</measurement>
                    <measurement group_id="O4" value="NA">Insufficient data to define due to assay censoring.</measurement>
                    <measurement group_id="O5" value="NA">Insufficient data to define due to assay censoring.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GW630200, n=0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA">Insufficient data to define due to assay censoring.</measurement>
                    <measurement group_id="O3" value="NA">Insufficient data to define due to assay censoring.</measurement>
                    <measurement group_id="O4" value="NA">Insufficient data to define due to assay censoring.</measurement>
                    <measurement group_id="O5" value="NA">Insufficient data to define due to assay censoring.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK932009, n=0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA">Insufficient data to define due to assay censoring.</measurement>
                    <measurement group_id="O3" value="NA">Insufficient data to define due to assay censoring.</measurement>
                    <measurement group_id="O4" value="NA">Insufficient data to define due to assay censoring.</measurement>
                    <measurement group_id="O5" value="NA">Insufficient data to define due to assay censoring.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax of GW642444 and Its Metabolites GI179710, GW630200, and GSK932009, After a Single Dose of GW642444</title>
        <description>Blood samples were collected pre-dose and at 2, 5, 10, 20, and 30 minutes, 1, 2, 4, 6, 8, 10, and 24 hour post-dose. Blood samples were analyzed for GW642444 and its metabolites GI179710, GW630200 and GSK932009, using a high performance liquid chromatography/mass spectrometry/mass (HPLC/MS/MS) spectrometry. The Time to maximum plasma concentration (Tmax) was determined from the concentration time data by non-compartmental methods. Assay censoring refers to some of the values being below the limit of quantification such that this parameter could not be defined.</description>
        <time_frame>Day 1 of each treatment period (up to Study Day 54)</time_frame>
        <population>PK Population: all participants who received at least one dose and for whom a PK sample was obtained and analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O2">
            <title>GW642444M 25 µg</title>
            <description>Participants received GW642444M 25 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O3">
            <title>GW642444M 50 µg</title>
            <description>Participants received GW642444M 50 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O4">
            <title>GW642444M 100 µg</title>
            <description>Participants received GW642444M 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
          <group group_id="O5">
            <title>GW642444H 100 µg</title>
            <description>Participants received GW642444H 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax of GW642444 and Its Metabolites GI179710, GW630200, and GSK932009, After a Single Dose of GW642444</title>
          <description>Blood samples were collected pre-dose and at 2, 5, 10, 20, and 30 minutes, 1, 2, 4, 6, 8, 10, and 24 hour post-dose. Blood samples were analyzed for GW642444 and its metabolites GI179710, GW630200 and GSK932009, using a high performance liquid chromatography/mass spectrometry/mass (HPLC/MS/MS) spectrometry. The Time to maximum plasma concentration (Tmax) was determined from the concentration time data by non-compartmental methods. Assay censoring refers to some of the values being below the limit of quantification such that this parameter could not be defined.</description>
          <population>PK Population: all participants who received at least one dose and for whom a PK sample was obtained and analyzed</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GW642444,n=0, 20, 19, 8, 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.175" lower_limit="0.03" upper_limit="2.00"/>
                    <measurement group_id="O3" value="0.200" lower_limit="0.08" upper_limit="1.00"/>
                    <measurement group_id="O4" value="0.425" lower_limit="0.15" upper_limit="1.03"/>
                    <measurement group_id="O5" value="0.500" lower_limit="0.20" upper_limit="2.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GI179710,n=0, 0, 4, 7, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA">Insufficient data to define due to assay censoring.</measurement>
                    <measurement group_id="O3" value="0.140" lower_limit="0.0" upper_limit="0.18"/>
                    <measurement group_id="O4" value="0.170" lower_limit="0.07" upper_limit="0.33"/>
                    <measurement group_id="O5" value="NA">Insufficient data to define due to assay censoring.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GW630200, n=0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA">Insufficient data to define due to assay censoring.</measurement>
                    <measurement group_id="O3" value="NA">Insufficient data to define due to assay censoring.</measurement>
                    <measurement group_id="O4" value="NA">Insufficient data to define due to assay censoring.</measurement>
                    <measurement group_id="O5" value="NA">Insufficient data to define due to assay censoring.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK932009, n=0, 0, 0, 0, 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="NA">Insufficient data to define due to assay censoring.</measurement>
                    <measurement group_id="O3" value="NA">Insufficient data to define due to assay censoring.</measurement>
                    <measurement group_id="O4" value="NA">Insufficient data to define due to assay censoring.</measurement>
                    <measurement group_id="O5" value="NA">Insufficient data to define due to assay censoring.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of the study medication to the end of treatment (up to Study Day 60).</time_frame>
      <desc>SAEs and non-serious AEs were reported for members of the Intent-to-Treat (ITT) Population, comprised of all participants randomized to treatment who received at least one dose of trial medication during the treatment period.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received placebo single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
        </group>
        <group group_id="E2">
          <title>GW642444M 25 µg</title>
          <description>Participants received GW642444M 25 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
        </group>
        <group group_id="E3">
          <title>GW642444M 50 µg</title>
          <description>Participants received GW642444M 50 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
        </group>
        <group group_id="E4">
          <title>GW642444M 100 µg</title>
          <description>Participants received GW642444M 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
        </group>
        <group group_id="E5">
          <title>GW642444H 100 µg</title>
          <description>Participants received GW642444H 100 µg single dose in the morning from the dry powder inhaler (DPI) from the DISKUS/ACCUHALER (one inhalation in the morning).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

